ImmunityBio, Inc. — Director's Dealing 2023

Jun 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2023-06-13

Reporting Person: Selecky Christobel (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-13	Stock Option (right to buy)	$2.99	A	158263	Acquired	2033-06-13	Common Stock (158263)	Direct

Footnotes

F1: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders.